Search
LX6171
go.drugbank.com/drugs/DB05180InvestigationalLX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia
Melanoma antigen recognized by T-cells 1
go.drugbank.com/drugs/DB15081InvestigationalMelanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Synonyms: Melanoma antigen recognized by T-cells 1GnRH pharmaccine
go.drugbank.com/drugs/DB05815ExperimentalThe pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation
Nadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigationalIt is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat. … [L44381] It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma _in situ_ (CIS)
TRGFT-201
go.drugbank.com/drugs/DB23064ApprovedInvestigational[L64070,L64071] It is the first regulatory T cell (Treg)-based immunotherapy approved by the FDA.[L64071] … [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic
VE303
go.drugbank.com/drugs/DB17794InvestigationalVE303 is under clinical development by Vedanta Biosciences.
Alvimopan
go.drugbank.com/drugs/DB06274ApprovedInvestigationalAlvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.
Flumazenil
go.drugbank.com/drugs/DB01205ApprovedInvestigationalFumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversi...
Hydroxyamphetamine
go.drugbank.com/drugs/DB09352ApprovedThe main use of hydroxyamphetamines as eye drops is the diagnosis of Horner's syndrome which is characterized by nerve lesions.
Porphobilinogen
go.drugbank.com/drugs/DB02272ExperimentalIt is generated by the enzyme ALA dehydratase, and converted into hydroxymethyl bilane by the enzyme porphobilinogen deaminase.